A detailed history of Legal & General Group PLC transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, Legal & General Group PLC holds 1,968 shares of ENTA stock, worth $18,755. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,968
Previous 1,968 -0.0%
Holding current value
$18,755
Previous $20,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$10.05 - $16.54 $2,803 - $4,614
279 Added 16.52%
1,968 $20,000
Q2 2024

Aug 14, 2024

SELL
$11.43 - $17.02 $605 - $902
-53 Reduced 3.04%
1,689 $21,000
Q1 2024

May 14, 2024

SELL
$10.08 - $17.46 $9,636 - $16,691
-956 Reduced 35.43%
1,742 $30,000
Q4 2023

Feb 15, 2024

SELL
$8.18 - $10.78 $78,863 - $103,929
-9,641 Reduced 78.13%
2,698 $25,000
Q3 2023

Nov 14, 2023

SELL
$11.09 - $22.13 $474,075 - $946,013
-42,748 Reduced 77.6%
12,339 $137,000
Q2 2023

Aug 14, 2023

SELL
$20.68 - $39.85 $19,749 - $38,056
-955 Reduced 1.7%
55,087 $1.18 Million
Q1 2023

May 15, 2023

SELL
$38.82 - $54.59 $13,198 - $18,560
-340 Reduced 0.6%
56,042 $2.27 Million
Q4 2022

Feb 14, 2023

BUY
$40.77 - $53.73 $57,241 - $75,436
1,404 Added 2.55%
56,382 $2.62 Million
Q3 2022

Nov 14, 2022

SELL
$48.29 - $71.27 $13,183 - $19,456
-273 Reduced 0.49%
54,978 $2.85 Million
Q2 2022

Aug 22, 2022

BUY
$38.13 - $76.93 $2,630 - $5,308
69 Added 0.13%
55,251 $2.61 Million
Q1 2022

May 16, 2022

BUY
$56.06 - $74.11 $896 - $1,185
16 Added 0.03%
55,182 $3.93 Million
Q4 2021

Feb 14, 2022

BUY
$60.19 - $97.37 $289,634 - $468,544
4,812 Added 9.56%
55,166 $4.13 Million
Q3 2021

Nov 15, 2021

BUY
$41.02 - $58.65 $154,358 - $220,699
3,763 Added 8.08%
50,354 $2.86 Million
Q2 2021

Aug 12, 2021

SELL
$43.76 - $53.11 $532,909 - $646,773
-12,178 Reduced 20.72%
46,591 $2.05 Million
Q1 2021

May 17, 2021

BUY
$41.69 - $54.95 $34,561 - $45,553
829 Added 1.43%
58,769 $2.9 Million
Q4 2020

Feb 12, 2021

BUY
$41.16 - $47.47 $4,609 - $5,316
112 Added 0.19%
57,940 $2.44 Million
Q3 2020

Nov 13, 2020

BUY
$43.36 - $53.53 $188,485 - $232,694
4,347 Added 8.13%
57,828 $2.65 Million
Q2 2020

Aug 14, 2020

BUY
$46.37 - $57.58 $102,524 - $127,309
2,211 Added 4.31%
53,481 $2.69 Million
Q1 2020

May 14, 2020

BUY
$40.22 - $62.0 $181,995 - $280,550
4,525 Added 9.68%
51,270 $2.64 Million
Q4 2019

Feb 13, 2020

BUY
$57.95 - $66.61 $174,951 - $201,095
3,019 Added 6.9%
46,745 $2.89 Million
Q3 2019

Nov 13, 2019

BUY
$60.08 - $88.17 $130,794 - $191,946
2,177 Added 5.24%
43,726 $2.63 Million
Q2 2019

Aug 14, 2019

BUY
$81.3 - $97.35 $28,861 - $34,559
355 Added 0.86%
41,549 $3.51 Million
Q1 2019

May 15, 2019

BUY
$69.08 - $105.66 $260,293 - $398,126
3,768 Added 10.07%
41,194 $3.94 Million
Q4 2018

Feb 15, 2019

BUY
$65.41 - $84.65 $719 - $931
11 Added 0.03%
37,426 $2.64 Million
Q3 2018

Nov 20, 2018

BUY
$85.46 - $126.37 $723,418 - $1.07 Million
8,465 Added 29.24%
37,415 $3.23 Million
Q2 2018

Aug 10, 2018

BUY
$81.85 - $120.51 $154,369 - $227,281
1,886 Added 6.97%
28,950 $3.32 Million
Q1 2018

May 17, 2018

BUY
$57.91 - $92.15 $46,617 - $74,180
805 Added 3.07%
27,064 $2.18 Million
Q4 2017

Feb 13, 2018

BUY
$45.65 - $59.37 $1.2 Million - $1.56 Million
26,259
26,259 $1.54 Million

Others Institutions Holding ENTA

About ENANTA PHARMACEUTICALS INC


  • Ticker ENTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,724,900
  • Market Cap $198M
  • Description
  • Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...
More about ENTA
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.